Novocure (NVCR) Stock
Medical device maker for non-invasive cancer treatment. Here's the price, business snapshot, and what's worth knowing about Novocure in November 2026.
NovoCure Limited (NVCR) develops and commercialises Tumour Treating Fields (TTFields), a non‑invasive therapy that uses alternating electric fields to disrupt cancer cell division. The company focuses on solid tumours, with approved indications and ongoing trials in brain, lung and other cancers. Revenue growth to date has been driven by increased adoption in the US and selected international markets, label expansions and expanding clinical evidence. Key considerations for investors include clinical trial outcomes, regulatory approvals, payer reimbursement and execution of commercial scale‑up. As a smaller-cap medical‑technology company (market cap about $1.58bn), NovoCure can be volatile: upside comes with execution and data risk, while setbacks in trials or reimbursement can affect the share price. This summary is educational and not personalised investment advice; potential investors should research further and consider risk tolerance and time horizon before investing.
Novocure (NVCR) Stock Forecast
Analyst price target, next 12 months
$33.75
+129.9% vs today's $14.68
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Novocure have a consensus 12-month target of $33.75, above the current price of $14.68.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Novocure's stock with a target price of $33.75, indicating strong growth potential.
Financial Health
Novocure is performing well with strong revenue and cash generation, indicating healthy financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Tumour Treating Fields
A differentiated technology targeting cell division that investors watch for clinical proof points, though trial outcomes can be binary and affect valuation.
Commercial Expansion
Revenue potential rests on wider adoption, geographic rollout and payer coverage; execution risk and reimbursement delays may temper near‑term growth.
Regulatory & Reimbursement
Approval decisions and payer policies shape market access; positive decisions can boost uptake, while unfavourable rulings can limit growth.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
